Patriot Financial Group Insurance Agency LLC Has $636,000 Holdings in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Patriot Financial Group Insurance Agency LLC reduced its stake in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 18.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 112,198 shares of the company’s stock after selling 24,696 shares during the period. Patriot Financial Group Insurance Agency LLC’s holdings in Voyager Therapeutics were worth $636,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Hsbc Holdings PLC acquired a new stake in Voyager Therapeutics in the 2nd quarter valued at approximately $128,000. The Manufacturers Life Insurance Company grew its holdings in shares of Voyager Therapeutics by 6.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 94,398 shares of the company’s stock valued at $747,000 after acquiring an additional 5,365 shares in the last quarter. Hunter Perkins Capital Management LLC increased its position in shares of Voyager Therapeutics by 3.3% in the third quarter. Hunter Perkins Capital Management LLC now owns 64,040 shares of the company’s stock valued at $375,000 after acquiring an additional 2,025 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Voyager Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after purchasing an additional 4,098 shares in the last quarter. Finally, Empowered Funds LLC grew its stake in shares of Voyager Therapeutics by 5.4% in the third quarter. Empowered Funds LLC now owns 44,809 shares of the company’s stock valued at $262,000 after buying an additional 2,278 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Voyager Therapeutics in a research report on Monday. Citigroup began coverage on Voyager Therapeutics in a research note on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Finally, Wedbush began coverage on Voyager Therapeutics in a report on Friday, November 29th. They set an “outperform” rating and a $11.00 price target for the company. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $15.97.

Voyager Therapeutics Stock Performance

Voyager Therapeutics stock opened at $5.60 on Wednesday. Voyager Therapeutics, Inc. has a 52-week low of $4.99 and a 52-week high of $10.66. The stock’s 50 day moving average price is $5.81 and its two-hundred day moving average price is $6.58. The stock has a market capitalization of $305.93 million, a price-to-earnings ratio of 7.89 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.29. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. The firm had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. During the same quarter last year, the firm posted ($0.59) earnings per share. On average, equities research analysts forecast that Voyager Therapeutics, Inc. will post -0.91 EPS for the current year.

Insider Activity

In related news, COO Robin Swartz sold 6,500 shares of the stock in a transaction on Monday, December 23rd. The stock was sold at an average price of $5.65, for a total value of $36,725.00. Following the completion of the sale, the chief operating officer now directly owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This represents a 5.47 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 10,778 shares of company stock worth $58,548 over the last 90 days. 4.53% of the stock is currently owned by corporate insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.